Skip to main content

paxlovid

Generic: NIRMATRELVIR

paxlovid: developed by 1 company · 2 clinical trials tracked · 1 FDA decision.

paxlovid evidence translation

What we can confirm

1 FDA record · 2 tracked trials

What it means

Source-backed records connect paxlovid to PFE; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could paxlovid → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Pneumonia
Development Pipeline (2)
CompanyPhase
PFIZER INC (PFE)Approved
PFIZER INC (PFE)Approved
Clinical Trials (2)

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19

NCT07157007·Phase 2·TRAW
Recruiting

Primary endpoint: Safety based on adverse events incidence

InterventionalRandomizedopen90 targetStarted 2025-09Completion 2026-0315 sites · Australia, South Korea, Taiwan, UzbekistanTraws Pharma, Inc.

Randomised Evaluation of COVID-19 Therapy

NCT04381936·Phase 3
Recruiting

Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)

InterventionalRandomizedopen70,000 targetStarted 2020-03Completion 2038-0916 sites · Belgium, Estonia, France, Ghana…University of Oxford
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro : also referred to as 3CL pro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment o(PFE)FDA ↗
NDA217188Type 1 - New Molecular EntityPriorityOralTablet

Frequently asked questions

Who is developing paxlovid?

paxlovid is being developed by PFIZER INC.

How many clinical trials involve paxlovid?

BioSniper tracks 2 clinical trials involving paxlovid.

What is paxlovid's latest FDA decision?

The most recent tracked FDA decision for paxlovid is Approval for 1 INDICATIONS AND USAGE PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro : also referred to as 3CL pro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment o, dated May 25, 2023.